美國

證券和交易委員會

華盛頓特區20549

附表13D/A

根據1934年證券交易法

(第六次修訂)*

達納斯公司

（發行人名稱）

普通股，每股面值$0.01

（證券種類名稱）

Y1968P 121

（CUSIP編號）

Finnbarr D. Murphy

Goodwin Procter LLP

第8大道620號

紐約，紐約10018

電話：（212）459-7257

如果申報人此前已在表格13G上報告本表13D的對象所涉及的獲取情況，並且 因爲規則13d-l（e）、13d-l（f）或13d-l（g）的緣故而報告此表格，請打勾此框☐。

接收通知和通信的授權人）

2024年11月8日

(需要提交本聲明的事項的日期)

如果申報人之前曾就本表格所述收購提交13G表格，並且因§ 240.13d-1(e)、240.13d-1(f)或240.13d-1(g)而提交本表格，請勾選下列方框 ¨.

票據以紙質形式提交的日程安排應包括簽署的原件和五份副本，包括所有附件。請參閱§ 240.13d-7(b)了解應將副本發送給哪些其他方。

*此封面其餘部分應填寫報告人就涉及該證券類別的初始申報，以及任何後續修正披露在先前封面提供的信息的修正申報。

在本封面的其餘部分所需的信息不應被視爲根據1934年證券交易法第18條的目的而「歸檔」，也不受該法規的責任，但應受到該法規的所有其他規定的約束（然而，行動但應遵守該法的其他所有規定（但請注意註釋）。

13D/A日程安排

13D/A日程表

(1)這些普通股由達那俄斯投資有限公司作爲達那俄斯信託的受託人持有(「DIL」)，該信託對這些普通股擁有唯一的投票權和處分權。達那俄斯信託的受益人是科斯塔斯博士及其直系家人。 DIL的董事會由四名成員組成，沒有成員是達那俄斯信託的受益人或科斯塔斯家族的成員，並對達那俄斯信託持有的股份擁有投票權和處分權。 科斯塔斯博士有權力撤換DIL作爲達那俄斯信託的受託人，因此，他可能被視爲有權益擁有這9,338,502股普通股。 這並不一定意味着證券的經濟擁有權。

This Amendment No. 6 to the Statement on Schedule 13D originally filed on August 16, 2010, as amended by Amendment No. 1 on August 14, 2018, Amendment No. 2 on December 2, 2019, Amendment No. 3 on September 14, 2021, Amendment No. 4 on April 15, 2022 and Amendment No. 5 on November 15, 2023 (the “ ”), ) relates to the common stock, par value $0.01 per share (「Common Stock」), of Danaos Corporation, a Marshall Islands corporation (the 「Company」), and is being filed by (i) Danaos Investment Limited, a company organized under the laws of New Zealand, as Trustee of the 883 Trust, a trust established under the laws of England and Wales (“DIL”), and (ii) Dr. John Coustas (“Dr. Coustas” and, together with DIL as Trustee of the 883 Trust, the “報告人”).

對以下每一項所給信息應被視爲通過引用納入所有其他項。 除非另有指示，所有空白項目保持不變，以下所修改的任何項目均被視爲修改並更新附表13D中現有項目。

根據聲明的第3項，現在在第3項最後一段之前添加以下段落：

查看對第4、5和6項的回覆，這些回覆已被納入參考。

Item 4 of the Statement is hereby amended by adding the following paragraphs to the end of Item 4:

This Amendment No. 6 updates the number of shares of Common Stock beneficially owned by the Reporting Persons to reflect that on November 8, 2024, 50,000 shares of Common Stock were granted to Dr. Coustas as a compensatory equity award and are held by DIL and 100,000 shares were acquired by DIL pursuant to the Amended and Restated Management Agreement as described in the next paragraph. This Amendment No. 6 also updates the percentage of outstanding Common Stock of the Company beneficially owned by the Reporting Persons, including to reflect repurchases under the Company’s common stock repurchase program.

DIL as Trustee of the 883 Trust is the beneficial owner of all of the outstanding shares of Danaos Shipping Company Limited (「Danaos Shipping」) and, in such capacity, is entitled to receive 100,000 shares of Common Stock, payable annually in the fourth calendar quarter of each year, as a management fee for the services of Danaos Shipping pursuant to the Amended and Restated Management Agreement (the 「Amended and Restated Management Agreement」), dated as of November 10, 2023, between the Company and Danaos Shipping. DIL as Trustee of the 883 Trust acquired 100,000 shares of Common Stock pursuant this agreement on November 8, 2024.

Each of the Shareholder Directors and each of the Reporting Persons acquired their shares of Common Stock for investment purposes. Each of the Shareholder Directors and each of the Reporting Persons reserve the right to change their intentions, as they deem appropriate. Depending on market conditions and other factors that they may deem material, each of the Shareholder Directors and each of the Reporting Persons may, in privately negotiated transactions, in the open market or otherwise, purchase additional shares of Common Stock and/or related securities, including pursuant to the Company’s DRIP, dispose of all or a portion of the shares of Common Stock or related securities that they now beneficially owns or may acquire hereafter, and/or enter into transactions that increase or hedge their economic exposure to the shares of Common Stock without affecting their beneficial ownership. Dr. Coustas serves as the Chief Executive Officer, President and Chairman of the Company, and Mr. Prokopakis serves as a director of the Company and Mr. Chatzis serves as Chief Financial Officer of the Company, and therefore each regularly engages in discussions with management of the Company, the board of directors of the Company, other shareholders of the Company and other relevant parties, which discussions may include matters ranging from the operations and conduct of the Company’s business to considering or exploring extraordinary corporate transactions including the events listed in Items 4(a) through 4(j) of Schedule 13D. In connection with these discussions, the Reporting Persons and/or either or the Shareholder Directors may, either directly or through one or more affiliates, determine to take any available course of action or to take no course of action and may at any time and from time to time take steps to further or implement such course of action, including any of the events listed in Items 4(a) through 4(j) of Schedule 13D. Any action or actions the Reporting Persons and/or either of the Shareholder Directors may undertake with respect to their investment in the Company or the operations and conduct of the Company’s business will be dependent upon their review of numerous factors, including those listed above, and the Reporting Persons and each of the Shareholder Directors specifically reserve the right to change their intentions, or to formulate plans and proposals, with respect to any or all of the matters described in this paragraph, subject to applicable law and regulations.

權利聲明書中的項目5已經被修改和重述如下：

DIL，作爲883信託的受託人，擁有9,338,502股普通股，佔已發行普通股總數的48.4%。DIL，作爲883信託的受託人，對這些普通股擁有獨立的表決權和行使控制權。883信託的受益人是Cousta博士及其直系家人。DIL的董事會由四名成員組成，沒有人是883信託的受益人或Cousta家族的成員，也沒有對883信託持有的股份擁有表決權和行使控制權。Cousta博士有某些權力可以撤換DIL作爲883信託的受託人，因此，他可能被視爲對這9,338,502股普通股具有有益所有權。這並不一定意味着對證券的經濟所有權。

Iraklis Prokopakis有益擁有200,270股普通股，約佔已發行普通股總數的1.0%。他對這些股份擁有獨立的表決權和行使控制權。

Evangelos Chatzis有益擁有73,000股普通股，佔已發行普通股總數的不到1.0%，包括於2024年11月8日獲得的23,000股普通股作爲補償獎勵。他對這些股份擁有獨立的表決權和行使控制權。

(a) 請查看本13D/A表格封面的第11和第13項目，了解每位報告人所持有的根據第1項目確定的證券類別的累計數量和百分比。

(b) 每位報告人擁有以下股數：

i. 單獨投票或指示進行投票的權力：請參閱本修訂案封面上的第7項。

ii. 共同投票或指示進行投票的權力：請參閱本修訂案封面上的第8項。

iii. 單獨處置或指示處置的權力：請參閱本修訂案封面上的第9項。

iv. 共同處置或指示處置的權力：請參閱本修訂案封面上的第10項。

(c) 除在本第6號修訂案中回答其他項目外，報告人和股東董事在過去60天未進行公司普通股的其他交易。

(d) 883 Trust的受益人包括庫斯塔博士及其家庭成員，在達那俄斯投資有限公司，作爲883 Trust的受託人名下的普通股中有權收取任何分紅或任何出售的收益。每位股東董事有權收取他擁有的普通股的任何股息或出售的收益。

(e) 不適用。

本聲明的第6項現通過添加以下段落予以修改

參見對於第3項、第4項和第5項的回覆，這些回覆已被引用

[本頁剩餘部分故意留白]

簽名

經過合理調查，並據每位簽署人的最佳知識和信念，每位簽署人均證明本第6號修正案中所載信息屬實、完整且正確。

日期：2024年11月13日